Categories: Health

Will the NHS ever pay for the new era of dementia drugs?


The first drug shown to slow the destruction of the brain in Alzheimer’s disease will not be available on the NHS after a decision by the medicine’s regulator.

The decision on funding lecanemab has caused upset and disappointment from those hoping the drug could help fight a horrible and devastating disease.

But the decision is also not a shock.

Lecanemab is not a “wonder drug”. The European Medicines Agency looked at the same data as the UK and concluded the drug should not be prescribed to anyone outside of a clinical trial.

But what would it take to get an Alzheimer’s-slowing drug covered by the NHS?

The National Institute of Health and Care Excellence has the job of working out what is a good use of taxpayers’ money. It is where the emotion, desperate need and lobbying for therapies come up against the cold, hard calculations of cost-effectiveness.

Dementia drugs that help manage symptoms, such as confusion, have been approved in the past.

But this is the first time a drug that changes the course of the disease has been assessed. This is a more familiar experience in other diseases. Earlier this summer the cancer drug Enhertu, which can extend the lives of some people with incurable breast cancer, was rejected, external because it was too expensive.

But even very expensive drugs – I reported on a one-off gene therapy that has an official cost of £2.6m – can be approved if the benefit is big enough.

Lecanemab has issues with its effectiveness, its cost and also its safety.

It was lauded for being the first drug to do something, anything, to slow the course of Alzheimer’s disease. For a field that had faced repeated failure, this was a truly significant moment when the data came out in 2022. But as I wrote at the time, the effect is small.

Lecanemab does not cure, reverse or halt Alzheimer’s disease. It slows the pace of decline.

In trials, the disease continued to rob people of their brain power, but that decline was slowed by around a quarter over the course of the 18 months of treatment. On an 18-point scale, ranging from normal to severe dementia, those getting the drug were 0.45 points better off.

How meaningful those effects are is still hotly debated by researchers.

Some argue they are giving people vital independence for longer. Others contend the effects are so small that a doctor would be unable to tell the difference between a patient getting lecanemab for 18 months and another getting a placebo (pretend treatment). Others say that patients should be allowed to make an informed choice about what is important to them.

The data on the drug came from a large-scale trial, external involving 1,795 volunteers with early stage Alzheimer’s. But those enrolled were healthier and younger than people when they are normally diagnosed. It raises questions of the drug’s “real-world” effectiveness in older, frailer people with multiple health conditions, and even “mixed” dementia which could be part Alzheimer’s and part another disease.

A more potent drug with a clearer impact on the course of Alzheimer’s disease could swing those cost-effectiveness calculations.

That could potentially still be lecanemab. It is possible that starting treatment even earlier in the disease or continuing treatment for longer would have greater effects. This is still unproven.

Or it could be that lecanemab shows the way and a future drug that follows in its footsteps could deliver the greater benefit. Medical research often needs the initial breakthrough that others can build on. The first HIV drugs eventually paved the way for modern anti-retroviral therapy that gives people a near-normal life expectancy.

Costs are the other side of this equation. A cheaper drug has to do less in order to meet that value-for-money threshold.



Source link

gulftimes

Recent Posts

Arab News | Russian cargo ship still on fire off Finland after attack

HELSINKI: A fire onboard ‌a Russian cargo ship that was struck by drones in the…

12 minutes ago

Arab News | Manufacturing, mining drive 12% rise in Saudi operating revenues: GASTAT

RIYADH: Saudi Arabia’s Operating Revenues Index rose 12.2 percent year on year in September, led…

13 minutes ago

Men's fishing group is the hook to better mental health

The men's fishing group that's helping their mental health. Source link

17 minutes ago

Ballistic Missile and Drone Attacks Intensify Across Gulf as Saudi Arabia and Bahrain Report Interceptions

Ballistic Missile and drone activity intensified across the Gulf region over the weekend, with Saudi…

1 hour ago

Arab News | Pakistan FM hopeful for US-Iran deal, warns against prolonged war

ISLAMABAD: Pakistan’s Deputy Prime Minister and Foreign Minister Ishaq Dar voiced optimism about reaching an…

4 hours ago

Arab News | South Korea education chief resigns amid AI cheating scandal

SEOUL: South Korea’s education minister resigned Sunday over an AI-assisted cheating scandal that erupted ahead…

4 hours ago